Christophe dombu
Stock Analyst at Kepler Capital
(0.11)
# 4,405
Out of 4,476 analysts
185
Total ratings
39.5%
Success rate
-12.6%
Average return
Main Sectors:
Stocks Rated by Christophe dombu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNN Smith & Nephew | Downgraded: Hold | n/a | $30.25 | - | 1 | Jun 4, 2026 | |
| LON: 0QBO Coloplast A/S | Initiated Coverage: Buy | kr 482.00 | $395.74 | +21.80% | 1 | May 20, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €810.00 | $817.40 | -0.91% | 33 | May 7, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | €23.50 | $26.90 | -12.64% | 19 | May 7, 2026 | |
| LON: SN Smith & Nephew plc | Maintained: Buy | 1,462p | $1,127.00 | +29.72% | 5 | May 6, 2026 | |
| EPA: VIRP Virbac SA | Maintained: Buy | €415.00 | $332.00 | +25.00% | 6 | Apr 17, 2026 | |
| SWX: KURN Kuros Biosciences AG | Maintained: Buy | CHF 38.00 | $19.12 | +98.74% | 9 | Apr 14, 2026 | |
| SWX: BSLN Basilea Pharmaceutica AG | Maintained: Buy | CHF 69.00 → CHF 70.00 | $54.30 | +28.91% | 27 | Apr 13, 2026 | |
| LON: 0HNZ Fagron NV | Maintained: Buy | €27.50 | $24.65 | +11.56% | 2 | Apr 9, 2026 | |
| EPA: MAAT MaaT Pharma SA | Maintained: Buy | €17.00 | $2.88 | +490.28% | 26 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €14.30 | $4.34 | +229.49% | 25 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.72 | +598.55% | 26 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €0.10 → €0.01 | $0.51 | n/a | 5 | Feb 7, 2025 |
Smith & Nephew
Jun 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $30.25
Upside: -
Coloplast A/S
May 20, 2026
Initiated Coverage: Buy
Price Target: kr 482.00
Current: $395.74
Upside: +21.80%
argenx SE
May 7, 2026
Maintained: Buy
Price Target: €810.00
Current: $817.40
Upside: -0.91%
Lakefront Biotherapeutics NV
May 7, 2026
Maintained: Sell
Price Target: €23.50
Current: $26.90
Upside: -12.64%
Smith & Nephew plc
May 6, 2026
Maintained: Buy
Price Target: 1,462p
Current: $1,127.00
Upside: +29.72%
Virbac SA
Apr 17, 2026
Maintained: Buy
Price Target: €415.00
Current: $332.00
Upside: +25.00%
Kuros Biosciences AG
Apr 14, 2026
Maintained: Buy
Price Target: CHF 38.00
Current: $19.12
Upside: +98.74%
Basilea Pharmaceutica AG
Apr 13, 2026
Maintained: Buy
Price Target: CHF 69.00 → CHF 70.00
Current: $54.30
Upside: +28.91%
Fagron NV
Apr 9, 2026
Maintained: Buy
Price Target: €27.50
Current: $24.65
Upside: +11.56%
MaaT Pharma SA
Mar 31, 2026
Maintained: Buy
Price Target: €17.00
Current: $2.88
Upside: +490.28%
Mar 26, 2026
Maintained: Buy
Price Target: €14.30
Current: $4.34
Upside: +229.49%
Mar 20, 2026
Maintained: Buy
Price Target: $12
Current: $1.72
Upside: +598.55%
Feb 7, 2025
Downgraded: Sell
Price Target: €0.10 → €0.01
Current: $0.51
Upside: n/a